<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2269">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992975</url>
  </required_header>
  <id_info>
    <org_study_id>19NS038</org_study_id>
    <nct_id>NCT04992975</nct_id>
  </id_info>
  <brief_title>Brain Iron Toxicity and Neurodegeneration - A 7T MRI Study</brief_title>
  <acronym>BITaN</acronym>
  <official_title>Brain Iron Toxicity and Neurodegeneration - An Ultrahigh Field (7T) MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nottingham University Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A longitudinal observational neuroimaging study of individuals with Early Onset Alzheimer's&#xD;
      disease during the prodromal phase, and matched control group - Ultrahigh Field MRI study at&#xD;
      7T&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to determine whether high resolution MRI at 7T and Quantitative&#xD;
      Susceptibility Mapping (QSM) can demonstrate a specific pattern of iron overload in&#xD;
      strategically important areas of brain as a sensitive marker of pathological Alzheimer's&#xD;
      disease i.e. patients with subjective or mild cognitive impairment associated with Amyloid or&#xD;
      tau pathological state in the cerebrospinal fluid.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative Susceptibility Mapping, QSM (from 7T MRI data) to hippocampal subfield volume loss at 1 year</measure>
    <time_frame>one year</time_frame>
    <description>Relationship between QSM at recruitment and to hippocampal subfield volume (QSM and hippocampal subfield volume are obtained from 7T MRI Susceptibility Weighted and T1 Weighted images)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cross-sectional and longitudinal changes in QSM in the hippocampal subfields</measure>
    <time_frame>one year</time_frame>
    <description>cross-sectional and longitudinal changes in QSM in the local hippocampal subfield QSM and volume loss after 1 year. QSM and hippocampal subfields volume will be obtained from 7T MRI data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuropsychological measures in relation to QSM and volume loss in hippocampal subfields</measure>
    <time_frame>one year</time_frame>
    <description>neuropsychological measures at 0 and 12 months in relation to QSM and volume loss in hippocampal subfields (adjusted for APOe). QSM and hippocampal subfield volume loss are obtained from 7T MRI Susceptibility Weighted and T1 Weighted images.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prodromal Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <description>Patients with Early Onset Alzheimer's disease (with known cerebrospinal fluid Amyloid/tau status) during prodromal or mild phase will have MRI of the brain at 7T, neurocognitive assessments, and blood test to check APOe status.&#xD;
Repeat neuroimaging and neurocognitive tests after one year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Age and gender matched individuals with normal cognition will have MRI of the brain at 7T, neurocognitive assessments and blood test to check APOe status.&#xD;
Repeat neuroimaging, neurocognitive tests after one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI at 7T</intervention_name>
    <description>MRI at 7T</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA samples will be stored and APOe status will be checked&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Alzheimer's Group: Preclinical or Prodromal Alzheimer's disease classified as either A+T-N-&#xD;
        or A+T+N- Control Group: individual within 1.5 standard deviation of normal cognition in&#xD;
        all tests&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Patients with pathological diagnosis of Alzheimer's disease according to the National&#xD;
             Institute on Aging and Alzheimer's Association, NIA-AA, criteria (Alzheimer's group)&#xD;
             or cognitively normal individuals within 1.5 standard deviation of normal in all tests&#xD;
             (control group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of mental capacity to consent to study involvement&#xD;
&#xD;
          -  Not speaking English before age 5 years&#xD;
&#xD;
          -  Learning disability&#xD;
&#xD;
          -  Schizophrenia&#xD;
&#xD;
          -  Substance misuse&#xD;
&#xD;
          -  Implanted devices not certified as compatible with ultra-high field MRI (e.g. cardiac&#xD;
             pacemaker)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Akram Hosseini</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>rebecca Boulton</last_name>
    <phone>01159249924</phone>
    <email>Rebecca.Boulton@nuh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haley Morris</last_name>
    <phone>01159249924</phone>
    <email>Haley.Morris@nuh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>East Midland</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Morris</last_name>
      <email>Haley.Morris@nuh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>September 28, 2022</last_update_submitted>
  <last_update_submitted_qc>September 28, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ultrahigh Field MRI</keyword>
  <keyword>7T MRI</keyword>
  <keyword>QSM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

